menu
    • menu

    Company profile for Novita Pharmaceuticals

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Novita Pharmaceuticals, founded in 2010 by Drs. Xin-Yun Huang and Jillian Zhang, is a clinical-stage biopharmaceutical company dedicated to developing first-in-class drugs targeting cancer metastasis and enhancing anti-cancer immune responses. Their proprietary fascin inhibitor technology aims to inhibit cell motility and metastasis, addressing the primary cause of over 90% of cancer-related deaths. Lead candidate NP-G2-044 ha...
    Novita Pharmaceuticals, founded in 2010 by Drs. Xin-Yun Huang and Jillian Zhang, is a clinical-stage biopharmaceutical company dedicated to developing first-in-class drugs targeting cancer metastasis and enhancing anti-cancer immune responses. Their proprietary fascin inhibitor technology aims to inhibit cell motility and metastasis, addressing the primary cause of over 90% of cancer-related deaths. Lead candidate NP-G2-044 has shown promising pre-clinical results, reducing tumor growth and metastasis, and is currently undergoing Phase 2A clinical trials as both monotherapy and in combination with anti-PD-1 agents.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Novita PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Suite 19A 445 Park Avenue New York, NY 10022
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://novita-pharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novita Pharma Receives FDA Orphan Drug Designation For NP-G2-044
    Novita Pharma Receives FDA Orphan Drug Designation For NP-G2-044

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novita-pharmaceuticals-announces-fda-orphan-drug-designation-granted-to-np-g2-044-for-the-treatment-of-pancreatic-cancer-302658088.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Novita presents positive Phase 2 trial data on NP-G2-044 at 2025
    Novita presents positive Phase 2 trial data on NP-G2-044 at 2025

    22 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novita-highlights-positive-data-from-phase-2-trial-of-np-g2-044-in-patients-with-advanced-and-metastatic-solid-tumors-at-2025-asco-annual-meeting-302463713.html

    PR NEWSWIRE
    22 May 2025
    Share Share
    Novita Pharma Presents Phase 2 NP-G2-044 Data at 2025 ASCO Meeting
    Novita Pharma Presents Phase 2 NP-G2-044 Data at 2025 ASCO Meeting

    23 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novita-pharmaceuticals-announces-oral-presentation-of-phase-2-np-g2-044-data-at-the-2025-american-society-for-clinical-oncology-asco-annual-meeting-302435089.html

    PR NEWSWIRE
    23 Apr 2025
    Share Share
    Novita Reports More Positive Ph 2 NP-G2-044 Data At AACR IO Meeting
    Novita Reports More Positive Ph 2 NP-G2-044 Data At AACR IO Meeting

    25 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/novita-presents-additional-positive-data-from-phase-2-trial-of-np-g2-044-in-patients-with-advanced-and-metastatic-solid-tumors-at-aacr-io-annual-meeting-302385274.html

    PR NEWSWIRE
    25 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search